ABSTRACT
Background Administration of pharmacogenomics (PGx) testing in clinical practice has been suboptimal, presumably due to lack of PGx education. Here, we aim to evaluate the standpoint of PGx testing among a diverse group of healthcare professionals (HCPs) through conducting surveys before and after training.
Materials & Methods Training modules were designed to cover 3 key learning objectives and deployed in 5 sections. A pre- and post-training survey questionnaire was used to evaluate participants self-assessments on employing PGx in clinical practice.
Results & Conclusion Out of all enrollments, 102 survey responses were collected. Overall, respondents agree on the benefits of PGx testing, but have inadequate self-efficacy and competency in utilizing PGx data. Our results show that training significantly improve these, and even leading to greater anticipation of PGx adoption.
Competing Interest Statement
F.A., C.M., K.I.J., L.S. and A.I. are employees of Nalagenetics Pte Ltd. A.I. and L.S. has financial holdings in Nalagenetics Pte Ltd. Resources for conducting training and surveys were sponsored by Nalagenetics Pte Ltd. None of the respondents received incentive except for FGD participants who received a small compensation for their transport and time.
Funding Statement
Resources for conducting training and surveys were sponsored by Nalagenetics Pte Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board (IRB No. 038/KEPK/III/2018 for Indonesia; 2017/007 for Singapore). Written consent was obtained from FGD participants, highlighting voluntary participation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Will individual participant data be available (including data dictionaries)? Yes What data in particular will be shared? Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). What other documents will be available? None When will data be available (start and end dates)? Immediately following publication. No end date. With whom? Anyone who wishes to access the data. For what types of analyses? Any purpose. By what mechanism will data be made available? All data generate or analysed during this study are included in this published article and appendices. Request for additional material should be addressed to A.I.
